氨氯地平联合替米沙坦对原发性高血压患者血管内皮功能及生活质量的影响

  目的 探讨氨氯地平与替米沙坦对原发性高血压患者血管内皮功能及生活质量的影响。 方法 选择解放军第153中心医院2016-04至2017-05收治的原发性高血压患者74例,随机分为对照组(n=37,口服氨氯地平治疗)和研究组(n=37,口服氨氯地平+替米沙坦治疗),比较两组患者血压控制、内皮功能及生活质量改善效果等。 结果 治疗2、4、8周后,研究组患者平均舒张压、收缩压水平均低于对照组(P<0.05);治疗后,研究组ET、LOP水平均显著低于对照组(t=8.410、18.329,P<0.05),NO、SOD水平显著高于对照组(t=14.834、6.515,P<0.05);研究组治疗后GQOLI-74量表中4个维度评分均显著高于治疗前,同时显著高于对照组(P<0.05);两组不良反应发生率分别为10.81%、13.51%,组间对比无统计学差异。 结论 给予原发性高血压患者氨氯地平+替米沙坦治疗,可获得更理想血压控制效果,能改善患者血管内皮功能,提高患者生活质量,且不会增加不良反应。

Effect of amlodipine and telmisartan on vascular endothelial function in patients with essential hypertension and on quality of life

Objective To evaluate the effect of amlodipine and telmisartan on the endothelial function of patients with essential hypertension and on quality of life of patients.Methods Seventy-four patients with primary hypertension treated at No. 153 Central Hospital between April 2016 and May 2017 were selected and equally divided into the control group(oral amlodipine treatment) and the study group(oral amlodipine and telmisartan treatment)to observe the effect of control of blood pressure, endothelial function and the improvement of quality of life.Results After 2, 4, 8 weeks, the average diastolic pressure and systolic pressure in the study group were significantly lower than those of the control group(P＜0.05). After treatment, the levels of ET and LOP in the study group were significantly lower than those of the control group(t=8.410、18.329,P＜0.05),but the levels of NO and SOD were significantly higher (t=14.834、6.515,P＜0.05).The scores of 4 dimensions in the GQOLI-74 scale of the study group were considerably increased after treatment and significantly higher than those of the control group(P＜0.05).The incidence of adverse reactions in the two groups was 10.81% and 13.51%, respectively, so there was no significant difference between them(χ²=0.462,P＞0.05).Conclusions Treatment of essential hypertension with amlodipine and telmisartan can better control blood pressure, improve the endothelial function and quality of life of patients without increasing adverse reactions.